Cellceutix Announces Dismissal of Class Action Lawsuit Filed by Rosen Law Firm
June 09, 2016 10:50 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 09, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
June 06, 2016 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - June 06, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...
Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week
May 31, 2016 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - May 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis
May 26, 2016 07:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - May 26, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
May 24, 2016 10:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - May 24, 2016) -
Clinical efficacy demonstrated in the highest dose (200mg) comparator arm
Compound shown to be safe and well-tolerated with a dose-related...
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow
May 11, 2016 09:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - May 11, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates
April 19, 2016 10:30 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - April 19, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
March 31, 2016 09:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - March 31, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis
March 30, 2016 10:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - March 30, 2016) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology,...
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis
March 17, 2016 10:00 ET
|
Cellceutix
BEVERLY, MA--(Marketwired - March 17, 2016) - Cellceutix (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology,...